Tenax Therapeutics (TENX) Net Cash Flow (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Net Cash Flow of -$820000.0 for Q2 2026, up 86.22% year-over-year from -$440332.0 in Q2 2025, and down 103.87% on a QoQ basis from $21.2 million in Q1 2026.
Tenax Therapeutics (TENX) Net Cash Flow (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at -$820000.0 in Q2 2026.
- Net Cash Flow for Q2 2026 came in at -$820000.0, up 86.22% year-over-year; the trailing twelve-month figure through Jun 2026 was $12.5 million (down 87.02% YoY), and the FY2025 annual result was $2.7 million, down 96.81% from the prior year.
- Net Cash Flow eased to -$820000.0 in Q2 2026, from $21.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $88.9 million in Q3 2024 and troughed at -$6.1 million in Q3 2025.
- A 5-year average of $6.2 million and a median of -$1.5 million in 2022 frame the typical range for Net Cash Flow.
- The largest YoY upside for Net Cash Flow was 4047.46% in 2024 against a maximum downside of 206.87% in 2024.
- A 5-year view of Net Cash Flow shows it stood at -$1.7 million in 2022, then rose by 19.81% to -$1.3 million in 2023, then slumped by 155.21% to -$3.4 million in 2024, then jumped by 48.05% to -$1.8 million in 2025, then surged by 54.16% to -$820000.0 in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were -$820000.0 in Q2 2026, $21.2 million in Q1 2026, and -$1.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Tenax Therapeutics | 80.73 Mn | 80.73 Mn | - | -820,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -820,000.00 |
| Jun 30, 2026 | -820,000.00 |
| Mar 31, 2026 | 21.19 Mn |
| Mar 31, 2026 | 21.19 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Mar 31, 2025 | 16.56 Mn |
| Mar 31, 2025 | 16.56 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Sep 30, 2024 | 88.91 Mn |
| Sep 30, 2024 | 88.91 Mn |
| Jun 30, 2024 | -3.17 Mn |
| Jun 30, 2024 | -3.17 Mn |
| Mar 31, 2024 | 2.76 Mn |
| Mar 31, 2024 | 2.76 Mn |